Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal and intragastric pH in patients with gastroesophageal reflux disease (GERD)

American Journal of Gastroenterology

Volumn 99, Issue 6, 2004, Pages 991-996

  Milkes, David ^b   Gerson, Lauren B ^b   Triadafilopoulos, George ^a  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ADULT; ARTICLE; BARRETT ESOPHAGUS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; ESOPHAGUS PH; FEMALE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; MALE; PATIENT MONITORING; PATIENT POSITIONING; PH MEASUREMENT; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; STANDING; STOMACH PH; SUPINE POSITION;

COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GASTRIC ACIDITY DETERMINATION; GASTROESOPHAGEAL REFLUX; HISTORY, 17TH CENTURY; HUMANS; HYDROGEN-ION CONCENTRATION; LINEAR MODELS; MALE; MONITORING, PHYSIOLOGIC; PROBABILITY; PROSPECTIVE STUDIES; PROTON PUMPS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 3142708981     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2004.30124.x     Document Type: Article

References (20)

1. Dent J, Brun J, Fendrick AM, et al. An evidence-based appraisal of reflux disease management - the Genval Workshop Report. Gut 1999;44:S1-S16.
2. Klinkenberg-Knol EC, Nelis F, Dent J, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: Efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000;118:661-9.
3. Richter JE, Kahrilas PJ, Johanson J, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: A randomized controlled trial. Esomeprazole Study Investigators. Am J Gastroenterol 2001;96:656-65.
4. Kahrilas PJ, Falk GW, Johnson DA, et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: A randomized controlled trial. Esomeprazole Study Investigators. Aliment Pharmacol Ther 2000;14:1249-58.
5. Bate CM, Griffin SM, Keeling PW, et al. Reflux symptom relief with omeprazole in patients without unequivocal oesophagitis. Aliment Pharmacol Ther 1996;10:547-55.
6. Carlsson R, Dent J, Watts R, et al. Gastro-oesophageal reflux disease in primary care: An international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol 1998;10:119-24.
7. Bytzer P. Goals of therapy and guidelines for treatment success in symptomatic gastroesophageal reflux disease patients. Am J Gastroenterol 2003;98:S31-39.
8. Holloway RH, Dent J, Narielvala F, et al. Relation between oesophageal acid exposure and healing of oesophagitis with omeprazole in patients with severe reflux oesophagitis. Gut 1996;38:649-54.
9. Johansson KE, Ask P, Boeryd B, et al. Oesophagitis, signs of reflux, and gastric acid secretion in patients with symptoms of gastro-oesophageal reflux disease. Scand J Gastroenterol 1986;21:837-47.
10. Bell NJ, Burget D, Howden CW, et al. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992;51(Suppl):59- 67.
11. Katzka DA, Castell DO. Successful elimination of reflux symptoms does not ensure adequate control of acid reflux in Barrett's esophagus. Am J Gastroenterol 1994;89:989-91.
12. Ouatu-Lascar R, Triadafilopoulos G. Complete elimination of reflux symptoms does not guarantee normalization of intra-esophageal acid reflux in patients with Barrett's esophagus. Am J Gastroenterol 1998;93:711-6.
13. Fass R, Sampliner RE, Malagon IB, et al. Failure of oesophageal acid control in candidates for Barrett's oesophagus reversal on a very high dose of proton pump inhibitor. Aliment Pharmacol Ther 2000;14:597-602.
14. Lagergren J, Bergstrom R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825-31.
15. Jamieson JR, Stein HJ, DeMeester TR, et al. Ambulatory 24-h esophageal pH monitoring: Normal values, optimal thresholds, specificity, sensitivity, and reproducibility. Am J Gastroenterol 1992;87:1102-11.
16. Srinivassan R, Katz PO, Ramakrishinan A, et al. Maximal acid reflux control for Barrett's oesophagus: Feasible and effective. Aliment Pharmacol Ther 2001;15:519-24.
17. Lind T, Rydberg L, Kyleback A, et al. Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000;14:861-7.
18. Hatlebakk JG, Camacho-Lobato L, Katz PO, et al. Omeprazole 20 mg b.i.d. vs lansoprazole 30 mg b.i.d. in control of intragastric acidity. Am J Gastroenterol 1998;93:1636.
19. Katz PO. Lessons learned from intra-gastric pH monitoring. J Clin Gastroenterol 2001;33:107-13.
20. Katz PO. Optimizing medical therapy for gastroesophageal reflux disease: State of the art. Rev Gastroenterol Dis 2003;3:59-69.